Daiichi Sankyo Company, Limited, announced the results of phase 3 clinical trials in Japan of the antiplatelet agent prasugrel hydrochloride... ...http://www.pharmabiz.com/NewsDetails.aspx?aid=98227&sid=2
The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to... ...http://www.expressbpd.com/pharma/management-pharma/cardiovascular-disease-market-set-to-grow-to-146-4-billion-dollars-by-2022-gbi-research/378003/
In Argentina, levels of smoking are rising in heart attack patients, according to a study presented at the Argentine Congress of Cardiology (SAC... ...http://www.medindia.net/news/smoking-rises-in-argentina-heart-attack-patients-164296-1.htm
NPPA has revised ceiling prices of 31 formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 and retail prices of 7... ...http://www.pharmabiz.com/NewsDetails.aspx?aid=98010&sid=2
Brilinta did not demonstrate a benefit over clopidogrel in a symptomatic peripheral artery disease patient population 04 October 2016... ...http://www.pressreleasepoint.com/astrazeneca-reports-top-line-results-brilinta-euclid-trial-patients-peripheral-artery-disease
Plavix clopidogrel tablets are an...